NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck
This article was originally published in The Pink Sheet Daily
Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.
You may also be interested in...
NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck
NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
NGM Phase IIb NASH Failure Could Darken Competitors’ Prospects
NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.